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Abstract In inflammatory disorders such as rheumatoid
arthritis, cytokines and danger signals are sensed by the
central nervous system, which adapts behavior and physi-
ologic responses during systemic stress. The central
nervous system can also signal the periphery to modulate
inflammation through efferent hormonal and neuronal
pathways. The brain and spinal cord are involved in this
bidirectional interaction. A variety of neuronal pathways
that modulate synovial inflammation have been implicated,
including the sympathetic and the parasympathetic
branches of the autonomic system. Another mechanism,
the dorsal root reflex, involves antidromic signaling along
somatic afferent fibers that influences joint inflammation by
releasing neuropeptides and other neuromediators in the
periphery. Some of the neurotransmitters and neurorecep-
tors involved have been identified in preclinical models and
represent novel targets for the treatment of rheumatic
diseases.
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Introduction
The concept that the central nervous system (CNS) and the
peripheral nervous system interact with the immune and
innate mediators of host defense is well-established. Many
mechanisms of this neuroimmune dialogue can influence
inflammation and immunity on a systemic scale or at the
regional and local levels. For instance, systemic control is
under the influence of the hypothalamic-pituitary axis,
which controls glucocorticoid release by the adrenal cortex
(the HPA axis), sex hormone levels by the gonads, and the
thyroid. The HPA axis provides an essential feedback
mechanism on inflammation and is often blunted in a wide
range of autoimmune and inflammatory diseases, including
systemic lupus erythematosus and rheumatoid arthritis. A
dynamic balance of glucocorticoid release is required to
maintain the homeostasis between excess inflammation and
response to stress. Pharmacologic or surgical interruption of
the HPA axis can increase mortality resulting from septic
shock, as seen in patients who require chronic glucocorti-
coid treatment.
The Autonomic Nervous System Link to Peripheral
Inflammation
The systemic control exerted by the HPA axis takes place
over hours, and other systems with similar feedback
mechanisms between the periphery and the brain or spinal
cord can control peripheral inflammation more rapidly and
directly. The neurological control of the HPA axis and the
autonomic system involves higher structures of the brain
and brainstem. Modulation of inflammation is also under
the control of somatic sensory fibers. Important steps in this
neurological processing and feedback occur in the spinal
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cord. The spinal cord then signals back to the periphery by
antidromic action potentials through afferent fibers [1]. The
effect is mainly proinflammatory, and somatic denervation
can actually protect from arthritis [2]. This antidromic
dorsal root reflex can influence inflammation through the
recruitment of inflammatory cells and by triggering
vasoactive edema.
In addition to the systemic control exerted by the HPA
axis and the local effects of the somatic fibers, the
autonomic nervous system is considered essential for the
control of the regional homeostasis at the level of individual
organs. The autonomic nervous system comprises two main
branches: the sympathetic and parasympathetic. They
constantly control the metabolism and visceral output and
exert both complementary and antagonizing functions.
Branches of the vagal nerve and sympathetic fibers
innervate immune organs, in which they can influence
peripheral immune responses. Noradrenaline and adrenaline
are the primary neurotransmitters of the sympathetic
nervous system (SNS). Noradrenergic sympathetic nerve
fibers originate from the spinal cord and innervate primary
and secondary lymphoid organs. The SNS also directly
innervates the joints and seems to plays a dual role in
synovial inflammation, both proinflammatory and anti-
inflammatory [3].
The vagus nerve that is formed by the 10th cranial
nerves is the main branch of the parasympathetic nervous
system. The immunoregulatory properties of the vagus
nerve were initially characterized during evaluation of the
inflammatory response in sepsis [4]. We describe how
parasympathetic activation can suppress inflammation and
how it relates to arthritis models. Similar to the HPA axis
and the dorsal root reflex, a neuroimmune feedback
mechanism modulates vagal activity. This mechanism has
been termed the cholinergic reflex in reference to the central
role of acetylcholine (ACh), the main neurotransmitter of
the parasympathetic system [5]. Experimental evidence
implicates the multifaceted effects of ACh in the central
and peripheral control of the cholinergic reflex. In the
periphery, the discovery that the anti-inflammatory effects
of this pathway depend on the α7 nicotinic receptor
initiated drug development efforts and preclinical testing
of selective agonists of this receptor [6].
Thus, the study of these pathways has unraveled potential
targets that are already validated in preclinical studies in
inflammatory models. One hallmark of neuroimmune path-
ways it that the neurotransmitters involved and their receptors
are often shared between the CNS and immune cells in the
periphery. Indeed, lymphocytes, macrophages, and fibroblast-
like synoviocytes (FLS) express an array of cell-surface
receptors for neurotransmitters. To safely advance pharmaco-
logic interventions to the clinical phase, it may be necessary to
design strategies that spare the function of these receptors in
the CNS. For instance, α7 agonists that penetrate the CNS are
already in clinical development for treatment of psychiatric
and degenerative diseases [7], while compounds without
blood–brain barrier permeability are being developed for
inflammatory diseases.
Spinal Control of Synovial Inflammation
Acute peripheral inflammation leads to a series of activation
events in the spinal cord. During the development of
experimental arthritis, somatosensory neurons become hyper-
excitable in response to innocuous stimuli (allodynia) [8].
This hyperexcitability is caused by C-fiber activation, and
afferent action potentials trigger the release of excitatory
amino acid glutamate and aspartate within the spinal cord
[9]. The resulting hyperalgesia is dependent on activation of
glutamate receptors of the N-methyl-D-aspartate (NMDA)
subtype and can be blocked by intrathecal administration of
NMDA receptor antagonists [10].
In return, the spinal cord can signal back to the periphery
via several neuronal routes to control different parameters
of local and regional inflammation. The first inflammatory
events that were shown to be provoked by neurogenic
inflammation were arteriolar vasodilation, plasma extrava-
sation, and hyperalgesia. These events are caused by the
release of inflammatory mediators such as substance P,
calcitonin gene-related peptide, or vasoactive intestinal
peptide by primary afferent fibers [11]. Antidromic action
potentials originate in the spinal cord toward the periphery
and travel through primary afferent neurons to mediate the
release of these neuromediators, mostly through small
afferent fibers such as C fibers.
These acute events do not usually lead to protracted
inflammation by themselves, unless tissue injury and cell
death occur. In synovitis, the transition to the chronic phase
usually involves the recruitment and inappropriate activa-
tion of cells of the innate immune system. For instance,
activated neutrophils and other resident sentinel cells of the
joint release destructive enzymes. The endogenous danger
signals released by the damaged tissue start and amplify
inflammation and can also increase input to the spinal cord
via the somatic afferents.
The ability of the spinal cord to regulate neutrophil
recruitment was first investigated in sterile inflammation.
Intrathecal administration of adenosine agonists decreased
neutrophil accumulation in a model of acute peripheral
inflammation provoked by the intradermal injection of
carrageenan [12]. The mechanism involves A1 receptor
stimulation in the spinal cord, which in turn inhibits
activation of NMDA receptors by excitatory amino acids
such as glutamate (Fig. 1). Thus, the same excitatory
mediators that activate spinal neurons during local inflam-
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mation also control an efferent mechanism involved in
neutrophil recruitment. Strikingly, the proinflammatory
effect of NMDA receptor activation in the spinal cord,
which can be antagonized by intrathecal adenosine, is
caused by a decrease in adenosine levels in the periphery.
The anti-inflammatory effect of adenosine in the periphery
is mediated by the A2 receptor expressed by neutrophils rather
than the A1 receptor that mediates NMDA suppression in the
spinal cord [12]. The efferent neuronal route is dependent on
sensory nerves because the effect of central A1 agonists was
abolished after rhizotomy, a surgical procedure that selec-
tively interrupts somatic sensory fibers, but not after
sympathectomy [13]. Notably, other studies also implicate
additional glutamate receptors, such as the AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor, in
reflex anti-inflammatory mechanisms.
These experiments demonstrate that the action of spinal
mechanisms on inflammation is not limited to acute
vasoactive events. The control exerted on the innate
immune system suggested that spinal cord events might
play a role during arthritis. The rapidity of the proinflam-
matory response evoked by antidromic signaling helps
control acute insults. As it is triggered by pain and
inflammation that are also cardinal symptoms of arthritis,
the possibility existed that it could aggravate joint disease.
Indeed, intrathecal administration of a selective A1
adenosine agonist (cyclohexyladenosine [CHA]) inhibited
inflammation and joint destruction in the rat model of
adjuvant arthritis [14]. The chondroprotective effects were
linked to a decreased activation of activator protein-1 in the
joints, which is a transcription factor involved in the
production of metalloproteinases.
The expression of the c-fos gene in the spinal cord, a
marker of neuronal activation, was increased during
adjuvant arthritis [14]. This is caused by painful and
inflammatory stimuli in the periphery that cause excitatory
amino acid release in the spinal cord. However, c-fos
expression is only transiently decreased after indirect
blockade of NMDA receptors by CHA, suggesting the
existence of additional spinal mechanisms [13].
New findings from neuropathic pain studies helped us
discover a previously unsuspected player in the processing of
pain and inflammatory signals by the spinal cord—the
microglial cells. Although glial cells were originally consid-
ered passive supporters of neurons in the CNS, they actually
contribute to the chronicity of neuropathic pain. It is mainly
the spinal microglial cells that contribute to neuronal
activation in these models. Strikingly, cytokines and signaling
pathways that mediate peripheral inflammation are also
expressed in the CNS during microglial activation: the
mitogen-activated protein kinases (MAPKs) and cytokines
interleukin (IL)-1 and tumor necrosis factor (TNF) [15].
The MAPK system, and the p38 MAPK in particular
play a central role in microglia activation in chronic pain
models [16–18]. After nerve injury, p38 is activated by
several stimuli, including osmotic stress and cytokines such
as IL-1 and TNF. Activated p38 augments the production of
the same inflammatory mediators, resulting in a self-
sustaining activation loop.
The role of p38 activation in the spinal cord was
investigated in adjuvant arthritis in the rat. In this model,
administration of a very small dose of a p38 inhibitor (0.1%
of the dose required for systemic administration) in the
Fig. 1 Schematic description of the main neuronal pathways involved
in the regulation of synovial inflammation. Vagal nerve firing leads to
acetylcholine (ACh) release in the periphery. ACh is an agonist for the
α7 nicotinic receptor on macrophages and fibroblast-like synoviocytes
(FLS) and decreases the release of cytokines and chemokines. Vagal
fibers are detected in peripheral organs such as the bronchi (dashed
lines), but not in the synovium. In organs not directly innervated by
the vagus, such as the spleen or the joints, vagal stimulation is
postulated to stimulate autonomic fibers to release norepinephrine
(NE), which in turn triggers ACh release via a non-neuronal
cholinergic system. The peripheral increase in ACh is sensed by the
nicotinic α7 receptor, which downregulates the release of proinflam-
matory cytokines. Central and intrathecal administration of p38
inhibitors stimulates the vagal nerve and decreases synovial inflam-
mation. In rheumatoid arthritis, loss of noradrenergic fibers inhibits
the anti-inflammatory action of the sympathetic system (β2 receptors)
and the vagal system. Stimulation of peripheral C-afferent fibers
releases excitatory amino acid (eg, glutamate) in the spinal cord,
which then binds to N-methyl-D-aspartate (NMDA) receptors to
decrease adenosine release by afferent fibers. Adenosine has an anti-
inflammatory effect in the periphery by binding to A2 receptors on
neutrophils and FLS and on central A1 receptors that inhibit NMDA
receptor activation. AG autonomic ganglion; IL interleukin; Mφ
macrophage; PMN polymorphonuclear leukocyte; Pp38 phospho-p38
mitogen-activated protein kinase; SB i. t. intrathecal SB203580 (p38
inhibitor); TNF tumor necrosis factor
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intrathecal space not only controlled pain but also reduced
inflammation and joint destruction [19]. TNF levels were
increased in the cerebrospinal fluid of arthritic rats, and
administration of a subclinical dose of etanercept intrathe-
cally also suppressed arthritis and spinal p38 activation.
Because p38 inhibition in the CNS also suppressed
intrathecal TNF, the most likely mechanism is that TNF
both induces and is induced by p38 activation. Recently,
another group demonstrated that intrathecal administration
of etanercept is also effective in the antigen-induced
arthritis model [20••].
The Vagal Cholinergic Pathway
The efferent mechanisms by which p38 inhibition in the
CNS downregulates arthritis are not completely understood.
Downstream of p38, an efferent neural route that ultimately
leads to vagus nerve activation appears to contribute.
Borovikova and colleagues [4] demonstrated that the vagus
nerve and cholinergic stimulation play an important role in
limiting the inflammatory response. The pathway is
composed of the efferent vagus nerve, the release of ACh
in the periphery by terminal fibers of the vagus, and
nicotinic receptors composed of the α7 subunit [6].
The vagus nerve is the major parasympathetic division of
the autonomic nervous system. It provides constant and rapid
regulation of organ function, including heart rate and gut
motility. The cholinergic vagal anti-inflammatory system was
first studied in acute models of inflammation. Initial work
focused on sepsis and endotoxemia models in which electric
stimulation of the vagus reduced cytokine production, includ-
ing TNF, and prevented shock [4]. An opposite effect was
obtained in vagotomized animals in similar models [21]. The
latter observation is explained by the existence of a reflex
mechanism by which cytokines released at the inflammatory
site activate afferent fibers of the vagus nerve. The afferent
arm of the cholinergic reflex routes through to the dorsal
motor nucleus of the vagus to stimulate the release of ACh,
the main neurotransmitter released by terminal vagal fibers.
Interruption of this homeostatic mechanism in vagotom-
ized animals aggravates inflammation. In animals with an
intact vagal nerve, this reflex operates to reduce the release
of proinflammatory cytokines in the periphery, thereby
contributing to the homeostasis of the system by reducing
inflammation.
Modulation of the Cholinergic Anti-inflammatory
Reflex by the Central Nervous System
The heart is innervated by the two divisions of the
autonomic nervous system. Their physiologic function is
to adapt and anticipate heart rate and output (eg, during a
fight or flight response). The cardiac autonomic tone can be
studied with noninvasive electrocardiogram recordings.
Mathematical analysis of the electrocardiogram can provide
quantitative measurements of sympathetic and parasympa-
thetic activities [22]. Vagal stimulation leads to ACh
release, which has a negative chronotropic effect on heart
rate. ACh was identified as the first neurotransmitter with
this historic observation. The cardiac vagal tone correlates
with the cholinergic anti-inflammatory reflex, at least in the
acute setting [23]. This characteristic can be exploited to
measure vagal activity by noninvasive methods in inflam-
matory models.
The quantitative measure of heart rate variability to
monitor vagal nerve activity has been used in preclinical
models to explore vagal outflow. We used computerized
frequency domain analysis, a standardized method of
quantifying vagal activity. Intrathecal administration of a
p38 inhibitor at the same dose that suppressed arthritis
increased vagal activity, suggesting a link between spinal
mechanisms and the cholinergic anti-inflammatory pathway
[24•]. This experimental protocol targets the delivery of the
p38 inhibitor to the lumbar spine. Because vagal activity is
controlled by the dorsal motor nucleus located in the floor
of the fourth ventricle, the increase in vagal activity seen
after p38 blockade in the lumbar spine suggests the
existence of an ascending neuronal tract to the dorsal motor
nucleus. Another p38 inhibitor, CNI-1493, can activate the
vagus when administered via intracerebroventricular injec-
tion, confirming the role of the p38 MAPK on vagal tone
[25]. Even though the anatomic route of administration is
different, this protocol was shown to decrease acute
peripheral paw inflammation in the carrageenan model
[26]. The anti-inflammatory effects on the paws were
abolished by vagotomy and mimicked by direct electrical
stimulation of the vagus.
The link between TNF-mediated spinal activation and
the autonomic system was also studied in a monoarticular
model of knee arthritis [20••]. Administration of etanercept
by the same intrathecal route at the lumbar spine level
reduced inflammation [19] and pain behavior, consistent
with the role of TNF in activation of p38 in spinal microglia
[17]. Electrocardiogram recordings showed that intrathecal
TNF prevented the increase in heart rate seen in arthritic
rats. This is compatible with an increased sympathetic drive
or a decreased vagal tone. Cardiac sympathetic drive was
increased in that study, but direct vagal measures were not
performed. Thus, spinal mechanisms also influence the
sympathetic system. The role of sympathetic nerves in joint
inflammation is discussed further below.
In addition to these spinal mechanisms, central cholin-
ergic muscarinic receptors modulate the vagal tone [23].
Different subtypes of ACh receptors in the brain regulate
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vagal output. The two main classes of ACh receptors are
classified by their response to agonists as muscarinic or
nicotinic. The control of vagal tone by brain structures is
mediated by muscarinic receptors of the M1 and M2
subtypes [23]. Activation of brain M1 receptors or
inhibition of presynaptic M2 receptors activates efferent
vagus activity and reduces peripheral TNF levels.
Increasing central ACh levels by targeting endogenous
mechanisms could provide a more physiologic approach to
re-establish the autonomic balance. Indeed, rheumatoid
arthritis patients have a decreased vagal output and
enhanced sympathetic tone [27]. The decrease in vagal
tone was inversely correlated with the level of the
proinflammatory factor high mobility group box-1 [28].
α7 Agonists also could be used because they were shown
to retain their efficacy in vitro on primary cells from
rheumatoid arthritis patients [29, 30, 31•].
Recently, an endogenous mechanism that regulates
acetylcholinesterase levels was discovered. In the steady
state, ACh levels are tightly and rapidly regulated by
cholinesterases. During inflammation, serum acetylcholin-
esterase levels decrease, which suppresses inflammation by
boosting ACh concentration. This effect is mediated by the
degradation of the mRNA encoding for acetylcholinesterase
by a microRNA (miR-132) [32]. miRNAs bind to mRNA
targets and usually prevent the production of the
corresponding protein. As miR-132 is expressed in the
brain and the periphery, its anti-inflammatory effect is
expected to target central and peripheral cholinergic
mechanisms of the vagal reflex.
The regulation of the vagal anti-inflammatory pathway
by brain acetylcholinesterases is confirmed by pharma-
cologic studies. In the rodent model of carrageenan-
induced paw inflammation, central stimulation of the
vagus by cholinesterase inhibitors significantly decreases
paw swelling [24•]. The high-frequency component of
heart rate variability, a measure of vagal activity that
correlates with its anti-inflammatory effects, is increased
by the same drug [24•]. Finally, administration of a
centrally acting muscarinic receptor antagonist decreased
the anti-inflammatory effect of the cholinesterase inhibitor
galantamine [33].
Peripheral Mediators of the Cholinergic
Anti-inflammatory Pathway
The peripheral anti-inflammatory effects of ACh released
by terminal vagus fibers are mediated by the α7 subtype
of nicotinic receptors. Nicotinic receptors are ligand-
gated ion channels formed by the hetero- or homocombi-
nation of 17 different subunits. The α7 receptor was first
identified in neurons as a homopentamer with high
calcium permeability. Several lines of evidence indicate
that the α7 receptor mediates most of the anti-
inflammatory effect of the vagal cholinergic pathway.
α7 Knockout mice have no overt basal phenotype but
suffer from increased inflammatory responses in various
models [21]. Vagal stimulation does not suppress
inflammation in these knockout mice. In vitro, application
of α7 agonists reduces proinflammatory cytokine
production by various cell types, including macrophages
and FLS [30, 31•]. α7 Agonists reduce inflammation in a
broad variety of animal models, including in collagen-
induced arthritis [34].
In acute inflammation, α7 expression by splenic macro-
phages is required for the anti-inflammatory effect of vagal
stimulation. The anatomic route is most likely indirect
because vagal cholinergic fibers are not detectable in the
spleen. Rather, recent findings suggest that a splenic non-
neuronal cholinergic system leads to ACh release during
the vagal anti-inflammatory reflex [35••]. This non-
neuronal cholinergic system may be controlled by cate-
cholaminergic endings of the splenic nerve found in the
vicinity of splenic macrophages.
Vagotomy very clearly antagonizes the anti-
inflammatory effect of electrical and pharmacologic
activation of the vagus in acute inflammation of the paws
[26]. In the murine collagen-induced arthritis model,
vagotomy can exacerbate arthritis, supporting a role for
the vagus in chronic synovitis [34]. However, the effect of
denervation in chronic models must be interpreted with
caution because undesired side effects of the procedures on
metabolic functions may confound the results. An effect on
the spleen could modulate the recirculation of macrophages
and lymphocytes to the synovium [35••]. Alternatively, the
synovium contains a non-neuronal cholinergic system and
catecholaminergic fibers [36]. The influence of the vagus
on the synovium could communicate through this system,
similar to the model proposed in the spleen [35••]. α7
Receptors are also highly expressed in the synovial intimal
lining and by cultured FLS. In vitro, α7 agonists suppress
the cytokines and chemokines produced by stimulated FLS
[30, 31•].
The mechanism by which α7 regulates inflammatory
responses depends on the model studied. α7 Receptor
stimulation antagonizes the nuclear factor-κB pathway in
macrophages in vitro [37]. Activation of a Janus kinase 2–
signal transducer and activator of transcription 3 anti-
inflammatory pathway was described in a murine model of
surgical intestinal inflammation [38]. In synoviocytes,
instability of IL-6 mRNA decreases IL-6 protein levels
[30]. In addition, it is not yet clear whether calcium fluxes
are required for the anti-inflammatory action of the α7
receptor, or if other nonionic signals are involved. Because
of the diversity of the mechanisms proposed, the develop-
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ment of α7 agonists is still mainly based on the calcium-
dependent neuronal model, which may not be fully relevant
to their application to inflammatory diseases such as
rheumatoid arthritis.
The Sympathetic Nervous System
The SNS also exerts complex control on joint inflammation
[3]. Along with the dorsal root reflex, it is a critical
proinflammatory component of neurogenic inflammation.
Sympathetic outflow can participate in the chronic phase of
arthritis and at this stage can exhibit both pro- and anti-
inflammatory actions. The duality of this system can be
explained in part by the fact that the SNS innervates the
joints and the secondary lymphoid organs.
For instance, systemic sympathectomy protects from
arthritis in experimental models, but only if performed
before immunization with the inducing protocol [39]. In the
late stages of experimental arthritis, the SNS markedly
decreases disease activity, and sympathectomy exacerbates
joint inflammation [40]. The sympathetic neurotransmitter
norepinephrine directly influences the T-cell–dependent
stage of experimental arthritis by activating CD4+ T cells
[41]. Thus, in experimental models, the proinflammatory
influence of the SNS occurs before the onset of synovitis.
In the later phases of experimental arthritis, the net effect of
the SNS is anti-inflammatory and can be enhanced by the
β-adrenergic agonist salbutamol [42].
Generalized loss of sympathetic fibers occurs in some
inflammatory diseases, potentially altering disease activity.
In rheumatoid arthritis, the decreased synovial sympathetic
innervation decreases norepinephrine levels. At low con-
centrations, this neurotransmitter predominantly binds to
the higher-affinity α-adrenoreceptors that are proinflamma-
tory [3].
Rational therapeutic approaches that target the SNS will
have to reconcile the detrimental influence of the SNS on
adaptive immunity and its anti-inflammatory function in the
joints. Sympathetic activity is globally increased in patients
with rheumatoid arthritis despite loss of fibers specifically
to the joint [27] and can potentially contribute to autoim-
munity. However, systemic sympathetic blockade could
increase the local inflammation in the joints. Cortisol has a
permissive effect on β-adrenergic signaling in synovial
tissue, and local administration of a β-agonist combined
with a corticoid has been suggested [43]. Sympathetic fiber
loss in the rheumatoid arthritis synovium can also contrib-
ute to the loss of synergy with endogenous or therapeutic
corticoids [43]. Counteracting the mechanisms that lead to
the depletion of sympathetic terminals in the synovium
could represent an elegant approach. Some of the factors
involved are described. For instance, increased concen-
trations of the soluble nerve factor neuropilin-2 synergize
with the repellent semaphoring 3F to deplete sympathetic
fibers in rheumatoid arthritis [44•].
Therapeutic Interventions
Among the different neuroimmune mechanisms that have
been described (Table 1), much of the current translational
research effort is focused on the vagal cholinergic pathway.
The elegant and detailed map of this pathway suggests
several possible strategies for treating inflammatory disor-
ders. Indeed, a recent Cochrane review confirmed that
nicotine itself is an effective agent in inflammatory bowel
disease [45].
Patients treated with cholinesterase inhibitors have
decreased levels of inflammatory cytokines compared with
controls [46]. Similar to the experimental setting, this
decrease could be caused by central activation of the vagus
and peripheral increase in ACh, the main anti-inflammatory
neurotransmitter released by parasympathetic fibers. Other
strategies could be developed to boost the anti-
inflammatory effect of the vagal output, such as targeting
Table 1 Nervous system control of peripheral inflammation
Neural route Vagus nerve Somatic afferent fibers Sympathetic fibers
Central mechanism Reflex stimulation of the dorsal motor
vagal nucleus by cytokines
Activation of NMDA receptors in the








Decrease cytokine and chemokine
release




Therapeutic targets Electrical stimulation of the vagus;
inhibition of p38 in the central nervous
system and spinal cord; cholinesterase
inhibitors; α7 agonists





NMDA N-methyl-D-aspartate; p38 p38 mitogen-activated protein kinase
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the central regulatory pathways with specific muscarinic
agonists, or by decreasing endogenous cholinesterase levels
with therapeutic microRNAs based on the effect of miR-
132 [32]. Electric vagal nerve stimulators that are already
approved for the treatment of neurological disorders also
could be envisioned [47]. The limitation of these
approaches for the treatment of severe synovitis is their
lack of specificity. Indeed, cholinergic side effects are
responsible for the narrow therapeutic range of cholinester-
ase inhibitors.
Selective α7 agonists are currently considered a safer
and more specific alternative for future therapeutic trials in
inflammatory diseases. Expression of the α7 receptor has
been detected on lymphocytes, macrophages, and FLS.
Several compounds are effective in preclinical in vivo and
in vitro models, including GTS-21, AR-R17779, and PNU-
282987. They differ by their selectivity toward other classes
of nicotinic receptors, with GTS-21 being less selective.
GTS-21 has already been tested in clinical trials for the
treatment of cognitive disorders and schizophrenia, with no
adverse events reported. AR-R17779 reduced arthritis in
the collagen arthritic model [34], whereas PNU-282987
decreased IL-6 and chemokine release by FLS in vitro [30].
Nicotinic receptor activation by α7 agonists causes a rapid
and long-lasting desensitization, which may impair the
therapeutic potential of these compounds [48]. Allosteric
modulators such as PNU-120596 can convert desensitized
receptors back to the open configuration. In neurons, this
increases the calcium signals. Most of the studies on the
properties of the α7 receptor were performed using patch
clamp experiments in overexpression systems. It is not yet
known whether these results also apply to inflammatory cell
types that express lower endogenous levels of the receptor.
Therefore, it is difficult to identify which type of agonists
should be used to treat inflammation.
Conclusions
Distinct neuroimmune mechanisms can influence the
outcome of generalized or localized inflammation in
inflammatory arthritis. The presence of a feedback loop is
characteristic of most neuroimmune homeostatic mecha-
nisms, including the HPA axis and the vagal cholinergic
reflex [5]. Increased glucocorticoid release is essential for
the metabolic response to stress, and cytokines such as IL-
1, IL-6, and TNF can influence the hypothalamus. The
same signals are believed to be involved in the activation of
the vagal anti-inflammatory reflex. Inflammatory cytokines
are also released in the spinal cord during pain and
inflammation. They participate in the activation of neuronal
and microglial cells and modify neuropathic pain responses
and neuronal feedback to the inflamed tissue [13, 14, 19].
Spatially restricted neural mechanisms can modulate
synovial inflammation. Three main neurological routes are
demonstrated to have an effect on synovitis in the experimen-
tal setting: antidromic signaling through somatic afferents and
the two branches of the autonomic nervous system, the
parasympathetic and the sympathetic system. Autonomic
dysregulation is a hallmark of systemic autoimmune disease,
including rheumatoid arthritis, providing indirect evidence for
a role of the sympathetic system and the cholinergic anti-
inflammatory pathway in human disease [26].
The role of the cholinergic anti-inflammatory pathway
has been evaluated in a wide range of experimental models
of chronic and acute inflammation. In the periphery, most
of its beneficial effects are linked to the stimulation of the
α7 nicotinic receptors. This subunit is expressed in the
synovial tissue of rheumatoid arthritis patients and by
primary FLS [30, 31•], supporting a link between the
cholinergic vagal pathway and synovial inflammation.
The α7 receptor is also expressed in the CNS and is
considered as a therapeutic target for the treatment of
schizophrenia and Alzheimer’s disease. Some α7-specific
compounds developed for the treatment of CNS diseases
also display anti-inflammatory activities in preclinical
models of arthritis [34]. Preclinical evaluation of these
compounds is still required to determine whether α7
agonists that do not penetrate into the CNS will have a
better therapeutic index.
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